Skip to main content

Incyte guidance

  • INCY · Nasdaq
  • Biotechnology
  • S&P 500
$120.97−0.60%Close 13 Nov 2026 · Market value $24.66B

In its results release of 29 Oct 2026 (Q3 FY2026), Incyte gave 1 forecast in figures, among them revenue of $5.21B to $5.30B for FY2026.

Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.

Latest guidance given with Q3 FY2026 results, 29 Oct 2026

MeasurePeriodGuidanceAs stated
RevenueFY2026$5.21B to $5.30BTotal net sales $5,210 - $5,300 million

Source: the company's earnings release.

Guidance against results last two years

The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.

MeasurePeriodLast guidanceRevisionsDeliveredResult
RevenueFY2026$5.21B to $5.30BRaised twice—To come

INCY in the terminal

Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.